ClotCare: Stroke and Heart Attack: A Class Effect of COX 2 Inhibitors?

ClotCare: Blood Clots, Stroke, Heart Attack

Thursday, November 21, 2024

Home | DVT/PE | Blood Clots | Coumadin/Warfarin | New Patients | Self Testing | Email List | Donate

Pick a Topic: Home New Postings Patient Postings Clinician Postings Join Our Email List Useful Web Links CE Opportunities Training Programs Guidelines DVT & PE Stories Editorial Board Financial Support About ClotCare DVT Coalition Contact Us Find info on a: Specific Medicine or Treatment Type of Medicine or Treatment Condition or Medical Procedure Lab Test Procedure Management Issue ClotCare complies with the HONcode standard for trustworthy health information: verify here. ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.	Stroke and Heart Attack: A Class Effect of COX 2 Inhibitors? Henry I. Bussey, Pharm.D. October 2004 Two leading authorities suggest that the increased risk of heart attack and stroke that resulted in the withdrawal of rofecoxib (Vioxx) is a class effect of the COX 2 inhibitors. Dr. Garret A. FitzGerald reviewed the available clinical data and explained how COX2 inhibitor-induced alterations in prostaglandin I-2 and thromboxane, together with potentiation of atherosclerosis, can lead to an increased risk of heart attack and stroke. Dr. Eric J. Topol offers additional comments supporting Dr. FitzGerald's position and significantly criticizes both the FDA and Merck for their delay in adequately addressing this risk. He further calls for a Congressional investigation into the role of the FDA and Merck in their handling of the available information. References 1. FitzGerald, GA. Coxibs and Cardiovascular Disease. N Engl J Med. 351;17: 1709-11. 2. Topol EJ. Failing the Public Health — Rofecoxib, Merck, and the FDA. N Engl J Med. 351;17: 1707-09.	Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org. ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters. New Postings: Click here to view full list of new postings
ClotCare Home \| New Postings \| Patient Postings \| Clinician Postings \| Join Our Email List \| Useful Web Links CE Opportunities \| Training Programs \| DVT & PE Stories \| Editorial Board \| Financial Support About ClotCare \| DVT Coalition \| Donate to ClotCare \| Contact Us
Key topics discussed on ClotCare include: Blood Clots \| Deep Vein Thrombosis (DVT) \| Pulmonary Embolism (PE) \| Atrial Fibrillation (A. Fib or AF) \| Heart Attack \| Stroke \| Transient Ischemic Attack (TIA) \| Mini Stroke \| Bleeding Complications \| Vascular Surgery \| Surgical Blood Clot Removal \| Warfarin \| Coumadin \| Lovenox \| Low Molecular Weight Heparin (LMWH) \| Heparin \| Anticoagulants \| Plavix \| Aspirin \| Antiplatelets \| Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved. Terms, Conditions, & Privacy \| Image Copyright Information 19260 Stone Oak Parkway, Suite 101 \| San Antonio, TX 78258 \| 210-860-0487 Send comments to webmaster@clotcare.org. Thursday, November 21, 2024